<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01438931</url>
  </required_header>
  <id_info>
    <org_study_id>DEX-301</org_study_id>
    <nct_id>NCT01438931</nct_id>
  </id_info>
  <brief_title>Clinical Study to Investigate the Efficacy and the Safety of DA-9501 in Sedation During the Surgery or Medical Procedure Without Intubation</brief_title>
  <official_title>Phase III Randomized Placebo-controlled Double Blind Comparative Study to Investigate the Efficacy and Safety of DA-9501 in Sedation During the Surgery or Medical Procedure Without Intubation Under Monitored Sedation Care</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospira, now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Maruishi Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospira, now a wholly owned subsidiary of Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and the safety of DA-9501
      (Dexmedetomidine) in sedation during the surgery or medical procedure without intubation
      under monitored sedation care.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase III, randomized, placebo controlled, double blind, parallel comparative study
      (Therapeutic confirmatory trial), to evaluate the efficacy and the safety of Dexmedetomidine
      in non-intubated patients who require sedation during surgery or medical procedure under
      monitored sedation care.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of patients who did not require rescue administration of propofol to achieve and maintain Observer's Assessment of Alertness/Sedation (OAA/S) Score ≤4 during the study drug administration</measure>
    <time_frame>Pre-dose, every 5 ± 2 minutes during study drug infusion and every 15 ± 2 minutes until 1 hour after study drug infusion. Before additional administration of sedative.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Administration frequency and dosage of propofol required to achieve and maintain OAA/S score ≤4 during the study drug administration</measure>
    <time_frame>After the start of study drug (20 ± 2 minutes), if the OAA/S score is 5.</time_frame>
    <description>If the OAA/S score is 5, 0.2 mg/kg of propofol as a sedative is administered intravenously by slow &quot;IV push&quot; and the administration is to be repeated until the target level of sedation (OAA/S score ≤4) is achieved.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first rescue administration of propofol</measure>
    <time_frame>≥15 minutes after the start of study drug infusion.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of patients who did not require rescue administration of fentanyl during the study drug administration</measure>
    <time_frame>After the surgery start, the administration of fentanyl is permissible as required to treat pain. In case of repeated dose, the dosing interval should be ≥15 minutes.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Administration frequency and dosage of fentanyl required during the study drug administration</measure>
    <time_frame>After the surgery start, the administration of fentanyl is permissible as required to treat pain. In case of repeated dose, the dosing interval should be ≥15 minutes.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of time spent OAA/S Score ≤4 during the study drug infusion</measure>
    <time_frame>Pre-dose, every 5 ± 2 minutes during study drug infusion and every 15 ± 2 minutes until 1 hour after study drug infusion. Before additional administration of sedative.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of time spent OAA/S Score 3 to 4 during the study drug infusion</measure>
    <time_frame>Pre-dose, every 5 ± 2 minutes during study drug infusion and every 15 ± 2 minutes until 1 hour after study drug infusion. Before additional administration of sedative.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to attain an Aldrete score ≥9 following discontinuation of the study drug infusion</measure>
    <time_frame>Every 15 ± 2 minutes until the total score value becomes ≥9.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Scale (VAS) score evaluation by Investigator or sub-investigator (ease of maintaining sedation level, hemodynamic stability, respiratory stability, subject's cooperativeness)</measure>
    <time_frame>Within 24 hours after completion of the study drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score evaluation of satisfaction and anxiety of the subject</measure>
    <time_frame>Within 24 hours after completion of the study drug administration (as much as possible)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">162</enrollment>
  <condition>Sedation</condition>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Loading infusion of Placebo over 10 minutes followed by maintenance infusion of Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DA-9501 0.5 mcg/kg group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Loading infusion of Dexmedetomidine 3.0 mcg/kg/hr over 10 minutes followed by maintenance infusion of Dexmedetomidine 0.2-0.7 mcg/kg/hr</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DA-9501 1.0 mcg/kg group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Loading infusion of Dexmedetomidine 6.0 mcg/kg/hr over 10 minutes followed by maintenance infusion of Dexmedetomidine 0.2-0.7 mcg/kg/hr</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DA-9501</intervention_name>
    <description>Dexmedetomidine hydrochloride variable dose</description>
    <arm_group_label>DA-9501 0.5 mcg/kg group</arm_group_label>
    <arm_group_label>DA-9501 1.0 mcg/kg group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient has signed and dated the Informed Consent after the study had been fully
             explained.

          2. Patient is male or female, at least 20 years of age when the Informed Consent is
             obtained.

          3. American Society for Anesthesiologists (ASA) I to III Class at the preoperative
             diagnosis.

          4. New York Heart Association (NYHA) classification is I to III (Only patients who need
             classification of cardiac performance.)

          5. Patient who requires sedation during the following elective surgery or procedure which
             require ≥30mins (expected time) without intubation under monitored sedation care.

             - Orthopedic, Otorhinologic, Oral surgeries, AV fistulas, Plastic, Excision of lesion,
             Breast biopsy, Catheter ablation, Vascular stents and AV shunt

          6. Patient who requires local or regional anesthesia.

        Exclusion Criteria:

          1. Patient who underwent general anesthesia within 7 days, or who received other study
             drugs within 30 days from the date of consent.

          2. Patient with &lt;92% SpO2 at the physical examination prior to the study drug
             administration, or ventilatory failure which requires intubation or Laryngeal Mask.

          3. Patient with central nervous system pathology which may lead to increased intracranial
             pressure, uncontrolled seizures, psychiatric disorder which may be confused with the
             response to sedation treatment.

          4. Patient who require neurosurgical or cerebrovascular catheter procedures or
             interventions.

          5. Patient who require general anesthesia, epidural anesthesia or spinal anesthesia for
             surgery or procedure.

          6. Patient who receives treatment by alpha-2 agonists or alpha-2 antagonists within seven
             days of scheduled surgery or procedure.

          7. Patient in whom opioids, DA-9501 or other alpha-2 agonists, or drugs which may be used
             in the study are contraindicated.

          8. Patient diagnosed unstable angina or acute myocardiac infarction within 6 weeks from
             the date of consent.

          9. Patient whose heart rate less than 50 bpm, systolic blood pressure less than 90 mm Hg
             by the physical examination prior to the study drug administration.

         10. Patient has third degree heart block, unless the patient has a pacemaker.

         11. Patient who has experienced an increase in alanine transaminase (ALT) and/or aspartate
             aminotransferase (AST) more than double the upper normal limit within 2 months of the
             date of consent, or who has a history of liver insufficiency.

         12. Pregnant or lactating woman.

         13. In the Investigator's or subinvestigator's opinion, patient has any symptom or factor,
             which might increase risk to the patient by conducting the study or preclude obtaining
             satisfactory study data.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Asahikawa Medical University Hospital</name>
      <address>
        <city>Asahikawa-City</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hyogo Prefectural Amagasaki Hospital</name>
      <address>
        <city>Amagasaki</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tsukuba University Hospital</name>
      <address>
        <city>Tsukuba</city>
        <state>Ibaraki</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yuaikai Toyomijo Chuo Hospital</name>
      <address>
        <city>Toyomijo</city>
        <state>Okinawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansai Medical University Hirakata Hospital</name>
      <address>
        <city>Hirakata</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka University Dental Hospital</name>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saitama Medical University International Medical Center</name>
      <address>
        <city>Hidaka</city>
        <state>Saitama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shimane University Hospital</name>
      <address>
        <city>Izumo</city>
        <state>Shimane</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tottori University Hospital</name>
      <address>
        <city>Yonago</city>
        <state>Tottori</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kagoshima University Medical and Dental Hospital</name>
      <address>
        <city>Kagoshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Japanese Red Cross Kyoto Daini Hospital</name>
      <address>
        <city>Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miyazaki Hospital</name>
      <address>
        <city>Miyazaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Okayama University Hospital</name>
      <address>
        <city>Okayama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kitano Hospital, The Tazuke Kofukai Medical Research Institute</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka Police Hospital</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka Saiseikai Nakatsu Hospital</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keio University Hospital</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Women's Medical University Hospital</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 21, 2011</study_first_submitted>
  <study_first_submitted_qc>September 21, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2011</study_first_posted>
  <last_update_submitted>July 23, 2015</last_update_submitted>
  <last_update_submitted_qc>July 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dexmedetomidine</keyword>
  <keyword>Sedation</keyword>
  <keyword>Non-intubation</keyword>
  <keyword>local anesthesia</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

